Table 2.
Outcome according to clinical characteristics and protein expression of CYB5A in the second cohort of radically resected pancreatic ductal adenocarcinoma patients*
| Univariate analysis | No. (%) | OS months (95% CI) | P† | DFS months (95% CI) | P† |
|---|---|---|---|---|---|
| 82 | 19.2 (15.4 to 23.0) | 12.0 (9.4 to 14.6) | |||
| Age, y | .30 | .68 | |||
| ≤65 | 43 (52) | 16.7 (6.0 to 27.4) | 12.0 (7.3 to 16.8) | ||
| >65 | 39 (48) | 19.2 (17.1 to 21.3) | 12.4 (8.3 to 16.5) | ||
| Sex | .86 | .80 | |||
| Male | 39 (48) | 18.4 (14.1 to 22.7) | 10.8 (8.6 to 19.5) | ||
| Female | 43 (52) | 21.1 (13.6 to 28.7) | 14.1 (8.6 to 19.5) | ||
| Resection status | .33 | .61 | |||
| R0 | 66 (80) | 19.2 (14.3 to 24.1) | 12.0 (8.9 to 15.1) | ||
| R1 | 16 (20) | 18.4 (16.3 to 20.5) | 10.8 (8.2 to 13.3) | ||
| Vascular infiltration | .35 | .67 | |||
| No | 38 (46) | 23.8 (12.6 to 35.0) | 12.0 (4.9 to 19.1) | ||
| Yes | 44 (54) | 18.4 (14.5 to 22.3) | 11.8 (9.4 to 14.1) | ||
| Neural infiltration | .47 | .86 | |||
| No | 23 (28) | 24.5 (8.1 to 40.9) | 12.0 (1.0 to 23.0) | ||
| Yes | 59 (72) | 18.8 (16.2 to 21.3) | 12.0 (9.6 to 14.4) | ||
| PanINs | .75 | 30 | |||
| No | 53 (64) | 18.4 (12.0 to 25.6) | 12.4 (9.7 to 15.0) | ||
| Yes | 29 (36) | 20.0 (14.3 to 25.7) | 10.8 (7.3 to 14.3) | ||
| WHO grading | .05 | .06 | |||
| 1–2 | 61 (74) | 20.5 (14.9 to 26.1) | 12.8 (8.4 to 17.3) | ||
| 3 | 21 (26) | 14.6 (7.3 to 21.8) | 7.5 (5.3 to 9.6) | ||
| AJCC stage | .16 | .24 | |||
| IIA | 13 (16) | 20.0 (18.5 to 21.9) | 12.0 (9.1 to 14.4) | ||
| IIB | 69 (84) | 18.4 (14.0 to 22.2) | 12.0 (9.0 to 15.0) | ||
| CYB5A protein expression | .02 | .02 | |||
| Low | 44 (54) | 16.7 (13.5 to 19.9) | 11.6 (8.3 to 14.9) | ||
| High | 38 (46) | 24.8 (12.8 to 36.9) | 16.4 (6.2 to 26.6) | ||
| Multivariable analysis | df | Risk of death HR (95% CI) | P‡ | Risk of relapse HR (95% CI) | P‡ |
| WHO grading | 1 | .05 | .14 | ||
| 1–2 | 0.6 (0.3 to 1.0) | 0.6 (0.4 to 1.2) | |||
| 3 | 1.0 (referent) | 1.0 (referent) | |||
| CYB5A expression | 1 | .02 | .03 | ||
| Low | 2.0 (1.1 to 3.6) | 1.8 (1.1 to 1.4) | |||
| High | 1.0 (referent) | 1.0 (referent) |
* AJCC American Joint Committee on Cancer; CI = confidence interval; df = degrees of freedom; DFS = disease-free survival; HR = hazard ratio; OS = overall survival; PanIN = pancreatic intraepithelial neoplasia; WHO = World Health Organization.
† Calculated using log-rank two-sided test.
‡ Calculated using Cox’s proportional hazards two-sided test.